New drug combo tested to shrink breast tumors before surgery
NCT ID NCT00616967
Summary
This study is testing if adding a drug called vorinostat to standard chemotherapy helps shrink breast tumors more effectively before surgery. It involves 68 women with operable, HER2-negative breast cancer who are randomly assigned to receive the standard chemo drugs or the standard drugs plus vorinostat. The main goal is to see if the combination leads to a better response, meaning no detectable cancer is found in the breast and lymph nodes after the treatment and before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anne Arundel Health System
Annapolis, Maryland, 21401, United States
-
Indiana University Purdue University of Indianapolis
Indianapolis, Indiana, 46202, United States
-
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410, United States
-
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, 35249, United States
Conditions
Explore the condition pages connected to this study.